2 weeks Ago By ABMN Staff
Canada Pension Plan Investment Board bought a new position in shares of Guardant Health, Inc. ( NASDAQ:GH – Free Report ) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 10,500 shares of the company’s stock, valued at approximately $303,000.
Several other institutional investors also recently bought and sold shares of GH. Canton Hathaway LLC purchased a new position in Guardant Health in the second quarter valued at $59,000. Byrne Asset Management LLC purchased a new position in shares of Guardant Health in the 2nd quarter valued at about $77,000.
Manchester Capital Management LLC acquired a new position in Guardant Health in the 1st quarter worth about $57,000. EntryPoint Capital LLC purchased a new position in Guardant Health during the first quarter worth approximately $75,000. Finally, Fullcircle Wealth LLC acquired a new stake in Guardant Health in the second quarter valued at approximately $211,000.
92.60% of the stock is currently owned by hedge funds and other institutional investors. Guardant Health Stock Performance Shares of Guardant Health stock opened at $22.
88 on Friday. The business’s 50 day moving average price is $27.92 and its 200 day moving average price is $25.
18. The company has a market cap of $2.80 billion, a price-to-earnings ratio of -5.
84 and a beta of 1.11. The company has a debt-to-equity ratio of 16.
70, a quick ratio of 6.07 and a current ratio of 6.40.
Guardant Health, Inc. has a one year low of $15.81 and a one year high of $37.
04. Analysts Set New Price Targets GH has been the subject of several research analyst reports. UBS Group upped their target price on Guardant Health from $32.
00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, August 21st. The Goldman Sachs Group upped their price objective on shares of Guardant Health from $28.
00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, July 17th. Citigroup lifted their target price on shares of Guardant Health from $40.
00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Jefferies Financial Group started coverage on shares of Guardant Health in a research report on Monday, June 3rd.
They set a “buy” rating and a $32.00 price target for the company. Finally, Canaccord Genuity Group raised their price target on shares of Guardant Health from $30.
00 to $38.00 and gave the company a “buy” rating in a research note on Tuesday, June 4th. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company.
According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.67. Check Out Our Latest Stock Report on Guardant Health Guardant Health Profile ( Free Report ) Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally.
The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. Featured Stories Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter .
.
